Company: INDP
Filing Date: 2025-09-02
Form Type: S-1
Source: 0001493152-25-012531
Chunk: 18

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-09-02
Form: S-1
Chunk 18
---
| ● | the                                                                                                                               
 risk of product liability claims, the availability of reimbursement, the influence of extensive and costly government regulation; |
| ● | our                                                                                                                               
 estimates regarding future revenue, expenses capital requirements and the need for additional financing; and                      |
| ● | our                                                                                                                               
 ability to maintain the listing of our shares of common stock on Nasdaq;                                                          |
| ● | our                                                                                                                               
 ability to continue as a going concern.                                                                                           |

As more fully described under the heading “Risk Factors” and elsewhere in this prospectus and under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and any subsequent Quarterly Report on Form 10-Q, which are incorporated by reference into this prospectus, many important factors affect our ability to achieve our stated objectives and to develop and commercialize any product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks and uncertainties set forth in our filings with the SEC. You should read this prospectus and the documents incorporated by reference herein and therein and any free writing prospectuses that we have authorized for use in this offering with the understanding that our actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

| 8 |

<div align='center'>USE OF PROCEEDS</div>

Assuming the maximum number of share are sold in this offering at an assumed combined public offering price of $6.40 per share and accompanying common warrants, which represents the closing price of our shares on Nasdaq on August 27, 2025, and assuming no issuance of pre-funded warrants in connection with this offering, we estimate the net proceeds of the offering will be approximately $4.3 million, after deducting the Placement Agent’s fees and estimated offering expenses payable by us and excluding the proceeds we may receive from the cash exercise of the common warrants to be issued in this offering, if any. However, this is a best efforts offering with no minimum